Nervgen Pharma (NGEN) Accounts Payables (2024 - 2026)

Nervgen Pharma (NGEN) has reported Accounts Payables for 3 consecutive years, with $3.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accounts Payables changed N/A year-over-year to $3.1 million in Q2 2026; TTM through Jun 2026 was $3.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $3.3 million, down 7.46% from the prior year.
• Accounts Payables was $3.1 million for Q2 2026 at Nervgen Pharma, down from $4.3 million in the prior quarter.
• Over five years, Accounts Payables peaked at $4.3 million in Q1 2026 and troughed at $3.1 million in Q2 2026.
• A 3-year average of $3.6 million and a median of $3.4 million in 2025 frame the typical range for Accounts Payables.
• The widest YoY moves for Accounts Payables: up 5.58% in 2025, down 5.58% in 2025.
• Over 3 years, Accounts Payables stood at $3.5 million in 2024, then slipped by 5.58% to $3.3 million in 2025, then retreated by 7.19% to $3.1 million in 2026.
• The last three Accounts Payables figures came in at $3.1 million (Q2 2026), $4.3 million (Q1 2026), and $3.3 million (Q4 2025), per Business Quant data.